These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24590634)

  • 21. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
    Brundage MD; Mackillop WJ
    J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.
    Di Maio M; Signoriello S; Morabito A; Rossi A; Maione P; Piantedosi F; Bilancia D; Cigolari S; Barbera S; Gebbia V; Daniele B; Robbiati SF; Illiano A; Ceribelli A; Carrozza F; Favaretto A; Piazza E; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2012 Jun; 76(3):457-64. PubMed ID: 22297086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
    Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
    Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
    Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
    Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
    Honecker F; Wedding U; Bokemeyer C;
    Onkologie; 2004 Dec; 27(6):583-8. PubMed ID: 15591721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
    J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
    Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
    Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Setting the bar for therapeutic trials in non-small-cell lung cancer: how low can we go?
    Johnson DH
    J Clin Oncol; 2014 May; 32(14):1389-91. PubMed ID: 24687823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.